Raymond Anton to Female
This is a "connection" page, showing publications Raymond Anton has written about Female.
Connection Strength
1.770
-
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
Score: 0.041
-
Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2021 09 01; 178(9):829-837.
Score: 0.041
-
Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
Score: 0.039
-
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020 05 01; 180(5):728-736.
Score: 0.038
-
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
Score: 0.037
-
Intraindividual changes in brain GABA, glutamate, and glutamine during monitored abstinence from alcohol in treatment-naive individuals with alcohol use disorder. Addict Biol. 2020 11; 25(6):e12810.
Score: 0.036
-
Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment na?ve individuals with alcohol use disorder. Neurosci Lett. 2019 07 27; 706:207-210.
Score: 0.035
-
Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
Score: 0.035
-
Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Na?ve Individuals with Alcohol Use Disorder Versus Light Drinkers. Alcohol Clin Exp Res. 2019 02; 43(2):221-226.
Score: 0.034
-
Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin Exp Res. 2018 12; 42(12):2453-2465.
Score: 0.034
-
Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
Score: 0.032
-
Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
Score: 0.032
-
Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017 07 04; 7(7):e1163.
Score: 0.031
-
Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. Alcohol Clin Exp Res. 2017 Jul; 41(7):1370-1380.
Score: 0.031
-
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
Score: 0.031
-
Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. Alcohol Clin Exp Res. 2017 May; 41(5):1054-1062.
Score: 0.030
-
Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
Score: 0.030
-
Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease. Alcohol Alcohol. 2017 Jan; 52(1):24-28.
Score: 0.029
-
Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol. 2016 Sep; 51(5):549-54.
Score: 0.029
-
The Reasons for Heavy Drinking Questionnaire: Factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs. 2016 Mar; 77(2):354-61.
Score: 0.028
-
Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res. 2016 Mar; 40(3):491-6.
Score: 0.028
-
Commentary on: ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res. 2014 Jul; 38(7):1826-8.
Score: 0.025
-
Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. Alcohol Alcohol. 2014 May-Jun; 49(3):261-70.
Score: 0.024
-
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
Score: 0.022
-
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
Score: 0.020
-
Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
Score: 0.020
-
Liver disease and HPLC quantification of disialotransferrin for heavy alcohol use: a case series. Alcohol Clin Exp Res. 2010 Nov; 34(11):1956-60.
Score: 0.020
-
The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010 Aug; 30(4):365-72.
Score: 0.019
-
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug; 29(4):334-42.
Score: 0.018
-
COMT genotype influences the effect of alcohol on blood pressure: results from the COMBINE study. Am J Hypertens. 2009 Jan; 22(1):87-91.
Score: 0.017
-
Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008 Oct; 103(10):1622-8.
Score: 0.017
-
Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res. 2008 Nov; 32(11):1954-61.
Score: 0.017
-
Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
Score: 0.016
-
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb; 28(1):5-12.
Score: 0.016
-
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
Score: 0.016
-
Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol. 2008 Mar-Apr; 43(2):192-7.
Score: 0.016
-
What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
Score: 0.015
-
Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study. Alcohol Clin Exp Res. 2006 Nov; 30(11):1878-83.
Score: 0.015
-
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17.
Score: 0.014
-
Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005 Oct; 15(5):723-8.
Score: 0.014
-
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
Score: 0.014
-
Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004 Nov; 28(11):1710-7.
Score: 0.013
-
A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Aug; 24(4):421-8.
Score: 0.013
-
Self-report and biomarker alcohol screening by primary care physicians: the need to translate research into guidelines and practice. Alcohol Alcohol. 2004 Jul-Aug; 39(4):325-8.
Score: 0.013
-
Following alcohol consumption, nontreatment-seeking alcoholics report greater stimulation but similar sedation compared with social drinkers. J Stud Alcohol. 2004 May; 65(3):330-5.
Score: 0.012
-
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
Score: 0.012
-
The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict. 2002; 11(2):141-50.
Score: 0.011
-
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
Score: 0.010
-
Adolescent Obsessive-Compulsive Drinking Scale: an assessment tool for problem drinking. J Natl Med Assoc. 2001 Mar; 93(3):92-103.
Score: 0.010
-
The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. Am J Psychiatry. 2021 06; 178(6):548-559.
Score: 0.010
-
Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 2000 Nov; 22(3):159-64.
Score: 0.010
-
The Utility of Carbohydrate-Deficient Transferrin in Identifying Chronic Alcohol Users in the Injured Patient: Expanding the Toolkit. J Surg Res. 2021 01; 257:92-100.
Score: 0.010
-
Piloting of the Just Say Know prevention program: a psychoeducational approach to translating the neuroscience of addiction to youth. Am J Drug Alcohol Abuse. 2021 01 02; 47(1):16-25.
Score: 0.010
-
Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcohol Clin Exp Res. 2020 08; 44(8):1625-1635.
Score: 0.010
-
Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
Score: 0.009
-
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
Score: 0.009
-
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
Score: 0.009
-
Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 08 01; 201:16-22.
Score: 0.009
-
The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav. 1999 May-Jun; 24(3):449-53.
Score: 0.009
-
Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis. 2019 Jun; 34(6):1053-1059.
Score: 0.009
-
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
Score: 0.009
-
Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 04 01; 197:228-235.
Score: 0.009
-
Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
Score: 0.009
-
Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. Alcohol Clin Exp Res. 2018 11; 42(11):2256-2265.
Score: 0.008
-
The effect of drinking intensity and frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res. 1998 Oct; 22(7):1456-62.
Score: 0.008
-
The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms. Addict Biol. 2019 09; 24(5):1109-1118.
Score: 0.008
-
Female alcoholic outpatients and female college students: a correlational study of self-reported alcohol consumption and carbohydrate-deficient transferrin levels. J Stud Alcohol. 1998 Sep; 59(5):555-9.
Score: 0.008
-
Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 07; 3(7):599-609.
Score: 0.008
-
Childhood hyperactivity, gender, and Cloninger's personality dimensions in alcoholics. Addict Behav. 1997 Sep-Oct; 22(5):649-53.
Score: 0.008
-
Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017 06; 4(6):469-476.
Score: 0.008
-
Behavior and physiology of social stress and depression in female cynomolgus monkeys. Biol Psychiatry. 1997 Apr 15; 41(8):871-82.
Score: 0.008
-
Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
Score: 0.007
-
Missing Data in Alcohol Clinical Trials with Binary Outcomes. Alcohol Clin Exp Res. 2016 07; 40(7):1548-57.
Score: 0.007
-
Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
Score: 0.007
-
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
Score: 0.007
-
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol. 1996 Mar; 31 Suppl 1:43-53.
Score: 0.007
-
Alcohol-related seizures and the kindling effect of repeated detoxifications: the influence of cocaine. Alcohol Alcohol. 1996 Mar; 31(2):135-43.
Score: 0.007
-
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol Suppl. 1996 Mar; 31(1):43-53.
Score: 0.007
-
The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb; 19(1):92-9.
Score: 0.007
-
Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
Score: 0.006
-
Carbohydrate-deficient transferrin and gamma-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res. 1994 Jun; 18(3):747-54.
Score: 0.006
-
Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014 Jun; 38(6):1706-11.
Score: 0.006
-
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep; 231(18):3799-807.
Score: 0.006
-
Risks of alcohol use disorders related to drinking patterns in the U.S. general population. J Stud Alcohol Drugs. 2014 Mar; 75(2):319-27.
Score: 0.006
-
Two methods for measuring carbohydrate-deficient transferrin in inpatient alcoholics and healthy controls compared. Clin Chem. 1994 Mar; 40(3):364-8.
Score: 0.006
-
Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2014 Jan; 19(1):41-9.
Score: 0.006
-
A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
Score: 0.006
-
Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord. 1993 Jun; 28(2):125-31.
Score: 0.006
-
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
Score: 0.006
-
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
Score: 0.006
-
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
Score: 0.006
-
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
Score: 0.006
-
Array-based profiling of DNA methylation changes associated with alcohol dependence. Alcohol Clin Exp Res. 2013 Jan; 37 Suppl 1:E108-15.
Score: 0.006
-
Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. J Hum Genet. 2012 Oct; 57(10):670-5.
Score: 0.006
-
Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol. 2012 Nov-Dec; 47(6):683-7.
Score: 0.006
-
Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav Brain Funct. 2012 May 16; 8:23.
Score: 0.005
-
Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry. 2012 Oct 15; 72(8):637-44.
Score: 0.005
-
ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One. 2011; 6(12):e28790.
Score: 0.005
-
Childhood adversity increases risk for nicotine dependence and interacts with a5 nicotinic acetylcholine receptor genotype specifically in males. Neuropsychopharmacology. 2012 Feb; 37(3):669-76.
Score: 0.005
-
A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet. 2011 Dec; 156B(8):960-8.
Score: 0.005
-
5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. Psychiatr Genet. 2011 Oct; 21(5):240-8.
Score: 0.005
-
GABRG1 and GABRA2 variation associated with alcohol dependence in African Americans. Alcohol Clin Exp Res. 2012 Apr; 36(4):588-93.
Score: 0.005
-
No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. Mol Psychiatry. 2012 Mar; 17(3):239-41.
Score: 0.005
-
Effect of ibuprofen on alcohol-induced teratogenesis in mice. Alcohol Clin Exp Res. 1991 Aug; 15(4):673-7.
Score: 0.005
-
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry. 2011 Sep 15; 70(6):528-36.
Score: 0.005
-
Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Jun; 156B(4):421-9.
Score: 0.005
-
Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage. 2011 May 01; 56(1):61-8.
Score: 0.005
-
Variation in NGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet. 2011 Jun; 156B(4):401-12.
Score: 0.005
-
Agitated depression in substance dependence. Drug Alcohol Depend. 2011 Jul 01; 116(1-3):163-9.
Score: 0.005
-
Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. Addict Biol. 2011 Jan; 16(1):124-32.
Score: 0.005
-
Perspectives on the pathophysiology of fetal alcohol syndrome. Alcohol Clin Exp Res. 1990 Dec; 14(6):807-12.
Score: 0.005
-
Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990 Sep; 147(9):1203-8.
Score: 0.005
-
Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology. 2010 Aug; 35(9):1921-31.
Score: 0.005
-
Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology. 2010 Jul; 35(8):1684-92.
Score: 0.005
-
Ethanol increases PGE and thromboxane production in mouse pregnant uterine tissue. Life Sci. 1990; 46(16):1145-53.
Score: 0.005
-
Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry. 2009 Nov; 66(11):1201-9.
Score: 0.005
-
Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety disorders. Addict Behav. 2010 Jan; 35(1):7-13.
Score: 0.004
-
Subtypes of major depression in substance dependence. Addiction. 2009 Oct; 104(10):1700-9.
Score: 0.004
-
CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64.
Score: 0.004
-
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep; 33(9):1582-8.
Score: 0.004
-
Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009 May; 33(5):925-30.
Score: 0.004
-
Population admixture modulates risk for alcohol dependence. Hum Genet. 2009 Jun; 125(5-6):605-13.
Score: 0.004
-
Association of variants in MANEA with cocaine-related behaviors. Arch Gen Psychiatry. 2009 Mar; 66(3):267-74.
Score: 0.004
-
Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009 Mar; 70(2):186-96.
Score: 0.004
-
Pro-opiomelanocortin gene variation related to alcohol or drug dependence: evidence and replications across family- and population-based studies. Biol Psychiatry. 2009 Jul 15; 66(2):128-36.
Score: 0.004
-
PGE measurement in mouse embryos and uterine/embryo tissue. Prostaglandins. 1988 Dec; 36(6):835-46.
Score: 0.004
-
OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
Score: 0.004
-
Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008 Jun 09; 168(11):1188-99.
Score: 0.004
-
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008 Apr; 65(4):466-75.
Score: 0.004
-
Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs. 2008 Jan; 69(1):5-13.
Score: 0.004
-
Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007 Nov; 31(11):1780-7.
Score: 0.004
-
Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007 Oct 10; 298(14):1641-51.
Score: 0.004
-
Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. Neuropsychopharmacology. 2008 Mar; 33(4):837-48.
Score: 0.004
-
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
Score: 0.004
-
Central nervous system prostaglandins and ethanol. Alcohol Clin Exp Res. 1987 Feb; 11(1):10-8.
Score: 0.004
-
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007 Feb; 31(2):221-7.
Score: 0.004
-
The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J Stud Alcohol. 2006 Sep; 67(5):700-6.
Score: 0.004
-
Cold pressor task reactivity: predictors of alcohol use among alcohol-dependent individuals with and without comorbid posttraumatic stress disorder. Alcohol Clin Exp Res. 2006 Jun; 30(6):938-46.
Score: 0.004
-
Pre-pregnancy alcohol experience attenuates typical decrease in gestational alcohol consumption in mice. Alcohol. 1986 Jan-Feb; 3(1):19-22.
Score: 0.003
-
Delusions of parasitosis: differential diagnosis and treatment. South Med J. 1985 Aug; 78(8):914-8.
Score: 0.003
-
Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005 Mar; 29(3):395-401.
Score: 0.003
-
Aspirin reduces alcohol-induced prenatal mortality and malformations in mice. Alcohol Clin Exp Res. 1984 Nov-Dec; 8(6):513-5.
Score: 0.003
-
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 Sep; 28(9):1362-70.
Score: 0.003
-
Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Compr Psychiatry. 2004 Jul-Aug; 45(4):304-10.
Score: 0.003
-
Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004 Feb; 29(2):393-402.
Score: 0.003
-
Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003 Dec; 23(6):553-62.
Score: 0.003
-
Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res. 2003 Sep; 27(9):1402-8.
Score: 0.003
-
Effect of prenatal alcohol exposure on consumption of alcohol and alcohol-induced sleep time in mice. Pharmacol Biochem Behav. 1983; 18 Suppl 1:325-9.
Score: 0.003
-
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr; 28(4):755-64.
Score: 0.003
-
Plants of Haiti used as antifertility agents. J Ethnopharmacol. 1982 Jul; 6(1):67-84.
Score: 0.003
-
Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend. 1981 Sep; 8(2):157-68.
Score: 0.003
-
Valepotriates, a new class of cytotoxic and antitumor agents. Planta Med. 1981 Jan; 41(1):21-8.
Score: 0.002
-
A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
Score: 0.002
-
A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000 Aug 01; 60(2):161-8.
Score: 0.002
-
Recurrent detoxification may elevate alcohol craving as measured by the Obsessive Compulsive Drinking scale. Alcohol. 2000 Feb; 20(2):181-5.
Score: 0.002
-
Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol. 2000 Jan; 61(1):55-63.
Score: 0.002
-
Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999 Sep; 23(9):1484-91.
Score: 0.002
-
Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
Score: 0.002
-
Carbohydrate-deficient transferrin and alcohol use in medical examiner cases. Alcohol. 1999 Jan; 17(1):7-11.
Score: 0.002
-
Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict. 1998; 7(1):14-23.
Score: 0.002
-
Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 Nov; 128(2):206-15.
Score: 0.002
-
Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem. 1995 Jun; 41(6 Pt 1):858-61.
Score: 0.002
-
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
Score: 0.002
-
Carbohydrate-deficient transferrin levels in a female population. Alcohol Clin Exp Res. 1995 Feb; 19(1):100-3.
Score: 0.002
-
Mood congruent and incongruent psychotic depressions: are they the same? J Affect Disord. 1994 Aug; 31(4):275-80.
Score: 0.002
-
A correlational study of carbohydrate-deficient transferrin values and alcohol consumption among Hispanic college students. Alcohol Clin Exp Res. 1994 Jun; 18(3):653-6.
Score: 0.002
-
Aspirin dose-dependently reduces alcohol-induced birth defects and prostaglandin E levels in mice. Teratology. 1991 Nov; 44(5):521-9.
Score: 0.001
-
Role of prostaglandins in alcohol teratogenesis. Ann N Y Acad Sci. 1989; 562:178-82.
Score: 0.001
-
Role of alcohol-induced hypothermia in mediating the teratogenic effects of alcohol in C57BL/6J mice. Alcohol Clin Exp Res. 1988 Jun; 12(3):412-6.
Score: 0.001
-
Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
Score: 0.001
-
Effect of indomethacin on alcohol-induced morphological anomalies in mice. Life Sci. 1987 Jul 20; 41(3):361-9.
Score: 0.001
-
Alcohol, pregnancy, and prostaglandins. Alcohol Clin Exp Res. 1987 Feb; 11(1):32-6.
Score: 0.001
-
Sensitivity to ethanol in female mice: effects of ovariectomy and strain. Life Sci. 1985 Oct 07; 37(14):1293-300.
Score: 0.001
-
Adrenalectomy reduces alcohol-stimulated activity: blood and brain alcohol content. Pharmacol Biochem Behav. 1984 Jun; 20(6):883-6.
Score: 0.001